RxDoctor Payments Data

Gina Canada, DO

Family Medicine · Connellsville, PANPI 1841414836

Payments from drug & device makers

$1,875in general payments, 2019–2025

Across 126 payments — averaging $14.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$313
  • Novo Nordisk$286
  • AstraZeneca$227
  • Lilly USA, LLC$175
  • Intuitive Surgical$93
  • Boehringer Ingelheim$89
  • plus $692 from 14 others

What the payments were for

  • Food & beverage$1,86099%
  • Education$151%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,875 in reported general payments places this provider in the 75th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$68,623
Medicare patients
183
Services billed
805

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide101$117,197
EliquisApixaban112$102,489
MounjaroTirzepatide38$57,625
JardianceEmpagliflozin52$49,418
LinzessLinaclotide30$23,503
Trelegy ElliptaFluticasone/Umeclidin/Vilanter25$23,303
TradjentaLinagliptin15$21,578
JanuviaSitagliptin Phosphate15$21,280
FarxigaDapagliflozin Propanediol13$12,687
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog17$11,458
Lantus SolostarInsulin Glargine,hum.Rec.Anlog79$11,399
Victoza 3-PakLiraglutide11$11,344
XareltoRivaroxaban14$11,270
MyrbetriqMirabegron21$10,679
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog11$9,571

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$286$117,197101 claims
PfizerEliquis$69$102,489112 claims
Boehringer IngelheimJardiance, Tradjenta$89$70,99667 claims
Lilly USA, LLCMounjaro$175$57,62538 claims
AbbVieLinzess, Synthroid$38$25,86454 claims
GSKTrelegy Ellipta$313$23,30325 claims
MerckJanuvia$37$21,28015 claims
AstraZenecaFarxiga$227$12,68713 claims
Johnson & JohnsonXarelto$56$11,27014 claims
Astellas Pharma US IncMyrbetriq$89$10,67921 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Connellsville

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →